產(chǎn)品搜索
產(chǎn)品分類(lèi)
相關(guān)文章
- BCMA靶點(diǎn)藥物細(xì)胞篩選模型
- PDGFRA靶點(diǎn)藥物細(xì)胞篩選模型
- IL6藥物細(xì)胞篩選模型
- 【分享】NIST開(kāi)發(fā)ERBB2- CNV標(biāo)準(zhǔn)品的一些思路
- 【連載-Toll樣受體系列2】TLR7激動(dòng)劑藥物細(xì)胞篩選模型
- ?LILRB4細(xì)胞篩選模型
- 人結(jié)腸癌細(xì)胞株的細(xì)胞形態(tài)是不太規(guī)則的三角形
- ATCC細(xì)胞的細(xì)胞破碎
- 抑制性檢查點(diǎn)靶點(diǎn)及其細(xì)胞篩選模型
- EGFR 20外顯子突變類(lèi)型標(biāo)準(zhǔn)品
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73302BCR-ABL1 E459K/BaF3

- 詳細(xì)內(nèi)容
CBP73302 | |
I. Introduction | |
Cell Line Name: | BCR-ABL1 [E459K]/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10%FBS |
Mycoplasma Status: | Negative |
II.Background | |
Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes. | |
III. Representative Data | |
1.WB of BCR-ABL1 [E459K]/BaF3 | |
2.Sanger of BCR-ABL1 [E459K]/BaF3 Figure 2. BCR-ABL1 [E459K]/BaF3 E549K
Figure 3. BCR-ABL1 [E459K]/BaF3 Fusion | |
3. Anti-proliferation assay Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 E459K Cells (C8). | |